Clinical Sequencing Core Facility for the Undiagnosed Diseases Network (UDN)

未确诊疾病网络 (UDN) 的临床测序核心设施

• 批准号: 9927850
• 负责人: Christine Eng
• 金额: $ 84.8万
• 依托单位: BAYLOR COLLEGE OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-09-22 至 2022-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9927850
• 关键词: Area; CLIA certified; Clinical; Collaborations; Community Networks; Computer Simulation; Core Facility; DNA Sequencing Facility; DNA sequencing; Data; Deposition; Diagnosis; Diagnostic; Diagnostic Procedure; Dideoxy Chain Termination DNA Sequencing; Disease; Enrollment; Environment; Evaluation; Extramural Activities; Family; Family member; Funding; Genes; Genetic; Genetic Predisposition to Disease; Goals; Individual; Infrastructure; Institution; International; Laboratories; Leadership; Medicine; Modality; Molecular; Molecular Diagnosis; Multiomic Data; Mutation; Participant; Pathway interactions; Patient Care; Patients; Phase; Phenotype; Physicians; Procedures; Protocols documentation; Quality Control; Rare Diseases; Reporting; Research; Research Personnel; Sampling; Secure; Sequence Analysis; Services; Site; Specific qualifier value; Standardization; Syndrome; United States; Update; Validation; Variant; Work; analysis pipeline; causal variant; clinical practice; clinical research site; clinical sequencing; college; cost; cost effective; data integration; exome; exome sequencing; experience; flexibility; gene discovery; genetic counselor; genetic disorder diagnosis; genome analysis; genome sequencing; improved; innovation; knowledge base; molecular diagnostics; multiple omics; proband; programs; research clinical testing; response; tool; transcriptome sequencing; whole genome

Project Summary/Abstract The objectives of this project are to support the goals of the Undiagnosed Diseases Network (UDN) by continuing our work during Phase I as the sequencing core facility to provide exome and genome sequencing for the network. The extramural opportunity “Clinical Sites for an Undiagnosed Diseases Network” created a consortium of institutions that built common protocols to improve patient access to state-of-the-art diagnostic methods, and to promote discovery and innovation in diagnosing and treating patients. Important to this coordinated effort is the use of common diagnostic modalities such that data can be readily shared among the sites. Therefore, the continued funding of a sequencing core facility that will provide state-of-the-art exome and genome sequencing for the network has been proposed. Baylor College of Medicine and the Baylor Genetics laboratory was selected as one of two sequencing cores for the UDN Phase I project performing whole exome sequencing for approximately 50% of the UDN participants. Baylor Genetics is a CAP and CLIA certified laboratory that developed whole exome sequencing as a clinical test in October 2011. Baylor Genetics has sequenced, analyzed, and provided final clinical reports of exome sequencing for over 11,000 patients with approximately 30-40% of cases receiving a molecular diagnosis. Our molecular clinical interpretation service comprises 16 ABMGG certified clinical molecular geneticists and four certified genetic counselors. To date, during UDN Phase I, the Baylor core performed exome sequencing for 256 probands and their family members for a total of 757 exomes. Whole exome sequencing comprised approximately 36% of the diagnoses made during UDN Phase I for patients and family members In response to the directives of the RFA, we will perform exome sequencing for probands and family members (3.5 individuals per proband) and deliver raw sequence reads and quality control metrics to the network within a two-week period followed by a clinical report. In addition, the Baylor core is now able to offer whole genome sequencing, analysis and clinical reporting in our CAP and CLIA certified laboratory, also with deposition of raw sequence reads within 2 weeks. In addition, we propose the option of RNASeq on a research basis for individuals with a non-diagnostic exome or genome analysis. These sequencing options can be weighed by the Steering Committee to provide the most efficient and cost-effective pathway to a molecular diagnosis for patients enrolled in this program.

项目摘要/摘要 该项目的目标是通过以下方式支持未诊断疾病网络的目标 在第一阶段期间继续我们作为测序核心设施的工作，以提供外显子组和基因组测序 为网络服务。校外机会“未诊断疾病网络的临床站点”创建了一个 构建通用协议以改善患者获得最先进诊断的机构联盟 方法，促进诊断和治疗患者的发现和创新。对这一点很重要 协调工作是使用公共诊断模式，以便数据可以容易地在 这些网站。因此，继续资助一个测序核心设施将提供最先进的 已经提出了该网络的外显子组和基因组测序。 贝勒医学院和贝勒遗传学实验室被选为两个测序核心之一 对于UDN第一阶段项目，对大约50%的UDN执行完整的外显子组测序 参与者。贝勒遗传学是一家CAP和CLIA认证的实验室，开发了整个外显子组 2011年10月，测序作为一项临床测试。贝勒遗传公司已经进行了测序、分析并提供了最终的 11,000多名患者外显子组测序的临床报告，约30-40%的患者接受了 一个分子诊断。我们的分子临床解释服务包括16个ABMGG认证的临床 分子遗传学家和四名注册遗传咨询师。迄今为止，在统一数字网络第一阶段，贝勒核心 对256名先证者及其家庭成员进行了外显子组测序，共获得了757个外显子组。整体 外显子组测序约占UDN I期患者诊断的36% 和家庭成员 根据RFA的指示，我们将对先证者和家庭进行外显子组测序 成员(每个先证者3.5人)，并将原始序列读数和质量控制指标传递给 在两周内建立网络，然后提交临床报告。此外，贝勒核心现在能够 在我们的CAP和CLIA认证实验室提供全基因组测序、分析和临床报告， 另外，在2周内沉积原始序列读数。此外，我们还提出了RNAseq选项 对有非诊断性外显子组或基因组分析的个体进行研究。这些测序 指导委员会可以权衡各种备选方案，以提供最有效和最具成本效益的途径 对参加该计划的患者进行分子诊断。